Trotabresib is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Glioblastoma Multiforme (GBM). According to Globaldata, it is involved in 4 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Trotabresibs valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Trotabresib is expected to reach an annual total of $7 mn by 2036 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Trotabresib Overview
CC-90010 is under development for the treatment of hematologic malignancies, solid tumors including advanced basal cell carcinoma, glioblastoma multiforme, diffuse astrocytoma, newly diagnosed glioblastoma. The therapeutic candidate is administered through the oral route. The drug candidate acts by targeting epigenetic target bromodomain and extra-terminal (BET) proteins. It was also under development for the treatment of NUT midline carcinoma, salivary gland carcinoma and endometrial carcinoma.
It was under development for relapsed and/or refractory Non-Hodgkin lymphomas including diffuse large B-cell lymphoma, follicular lymphoma or marginal zone lymphoma.
It was also under development for the treatment of anaplastic astrocytoma.
Bristol-Myers Squibb Overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, immunology, cardiovascular, and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.
The company reported revenues of (US Dollars) US$45,006 million for the fiscal year ended December 2023 (FY2023), a decrease of 2.5% over FY2022. In FY2023, the companys operating margin was 20.9%, compared to an operating margin of 20.9% in FY2022. In FY2023, the company recorded a net margin of 17.8%, compared to a net margin of 13.7% in FY2022.
The company reported revenues of US$11,865 million for the first quarter ended March 2024, an increase of 3.4% over the previous quarter.
For a complete picture of Trotabresibs valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.